

Product Data Sheet

Product Name: Satralizumab

Cat. No.: GC66342

Chemical Properties

Cas. No. 1535963-91-7

Formula

M.Wt

Solubility

Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

Satralizumab

Background

Satralizumab, a humanized monoclonal antibody, is a potent **Interleukine-6 (IL-6)** inhibitor. Satralizumab prevents dTAA formation and progression in *rattus norvegicus*. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research^{[1][2]}.

Satralizumab (120 mg, Subcutaneously, once every 2 weeks, for 4 weeks) prevents dTAA formation and progression in *rattus norvegicus*^[1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Animal Model: *Rattus norvegicus* (forty, male, 10-week-old, four equal groups)^[1]

Dosage: 120 mg

Administration: Subcutaneously, once every 2 weeks, for 4 weeks

Result: Prevented dTAA (descending thoracic aorta aneurysm) formation and progression.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA